Clinical Trial Update: 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2, Phase 3]

View source ↗

Summary

A 26-week Phase 2/3 study evaluated the efficacy, safety and tolerability of indacaterol in patients with chronic obstructive pulmonary disease; the trial is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Onbrez Breezhaler (indacaterol maleate)

Snippet

Sponsor: Novartis | Conditions: Pulmonary Disease, Chronic Obstructive, COPD | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2011-08-18